IMPACT FACTOR: 1.3
Short Name: Ann Breast Cancer
ISSN: 2640-8198
Publisher: MedDocs Publishers LLC
Majority of LBH+ patients undergo some form of systemic treatment and show relatively better clinical outcomes than LBH- patients. However, LBH- patients have poorer prognosis and may need more aggressive systemic approaches for improved treatment outcomes. Better differentiation of molecular subtypes is still a challenge and tumor protein p53 may be a potential marker for more refined risk stratification.
Aim: To review the surgical management of breast cancer based on the adoption of the available surgical options and resources in developing countries. Materials and methods: This review was undertaken at a university hospital with tertiary care facilities. All patients diagnosed with breast cancer between 2000-2018 were included. Demographic data and the offered surgical options were the focus of this review. The review categorized the data into two groups: mastectomy and Breast Conserving Surgery (BCS).
A 70 years old female of suburban descent presented to the breast specialty clinic with 10 years history of a left enlarging painless breast mass not associated with local or systemic symptoms. There were no associated comorbidities or family history of breast cancer. Systemic examination was unremarkable. Local breast examination revealed obvious breast asymmetry with a large 10 × 11-centimeter smooth, non-tender, mobile mass occupying the retro-areolar and central regions of the left breast...
Background: Previous work from our and other laboratories showed that Prostate-Derived Ets Factor (PDEF) is a highly expressed oncogenic driver in breast cancer. However, the characteristics of PDEF expression in breast cancer and its relationship to estrogen signaling and estradiol levels remain poorly understood. To gain insights into these objectives, we analyzed the Cancer Genome Atlas (TCGA) breast cancer cohort consisting of 1095 breast tumors and the associated clinical and molecular data.
Due to its high incidence breast cancer is still a major health problem worldwide since, although a high percentage of patients can be effectively cured there are still some concerns in patients’ management. Several new biomarkers and potential targets for therapy have been identified but still the effects on patients’ outcome is not fully satisfactory.
Background: Oncotype DX risk score, a clinically validated test that estimates the recurrence and predicts the likelihood of benefit from adjuvant chemotherapy in early ER\PR positive, node-negative breast cancer, it is calculated based on characteristics of 21 genes that define the ER status, Her2 neu status, tumor proliferation, and tumor invasion. NCCN guidelines recommend adjuvant endocrine therapy for low RS (<18) and systemic adjuvant chemotherapy for high RS (>30), but no clear consensus about chemotherapy role in intermediate RS.
Cell survival must exist in equilibrium with cell death in order to maintain proper organ development and cellular and tissue homeostasis. Several forms of cell death have been discovered and well characterized during the last years. One of the best studied form of cell death is apoptosis, which can be defined as an ordered and controlled way to program a cell to die. Apoptosis is essential for normal tissue turnover, development, differentiation and immune responses
Metal-containing polymers have shown good activity against MCF-7 and MDA-MB-231 human breast cancer cells. These cell lines represent about one half of the known human breast cancers. MDA-MB-231 (strain number 7233) cells are estrogen-independent; estrogen receptor negative while the MCF-7 (strain line 7259) cells are estrogen receptor (ER+) positive and the combination are used as a matched pair. Polyethers that contained the O-phenylene structural unit showed good inhibition ...
Background: Adjuvant treatment options for HER2-positive Early-Stage Breast Cancer (EBC) have grown in recent years. The addition of adjuvant trastuzumab therapy for one-year to standard chemotherapy has been shown in several Randomized Controlled Trials (RCTs) to improve Disease-Free Survival (DFS) and Overall Survival (OS) in patients with high-risk HER2-positive EBC. This study aimed to review the long-term outcome data for patients with HER2-positive EBC who were treated with adjuvant trastuzumab therapy in a designated cancer centre.
Women who have undergone surgical menopause due to a Bilateral-Salpingo-Oophorectomy (BSO), often require Hormone Replacement Therapy (HRT) to mitigate menopausal symptoms. The use of HRT has been shown to increase breast density and the risk of breast cancer in women with natural menopause. The purpose of this study was to evaluate breast density in women with breast cancer who received HRT after surgical menopause.
We always work towards offering the best to you. For any queries, please feel free to get in touch with us. Also you may post your valuable feedback after reading our journals, ebooks and after visiting our conferences.
Authors
Freya Schnabel*; Sarah Pivo; Esther Dubrovsky; Jennifer Chun; Shira Schwartz; Amber Guth; Deborah Axelrod
Department of Surgery, New York University Langone Medical Center, USA
Received: Mar 23, 2018
Accepted: Apr 18, 2018
Published Online: Apr 27, 2018
Authors
Quintyne KI1,2*; Woulfe B 3; Coffey JC 2,4; Gupta RK 2,3
1 Department of Public Health, HSE North-East, Ireland
2 Graduate Entry Medical School, University of Limerick, Ireland
3 Department of Medical Oncology, University Hospital Limerick (UHL), Ireland
4 Department of Surgery, UHL, Ireland
Received: Mar 21, 2018
Accepted: May 28, 2018
Published Online: June 07, 2018
Authors
Michael R Roner1*; Charles E Carraher, Jr2*; Kimberly Shahi1 ; Alisha Moric-Johnson1 ; Lindsey Miller1 ; Paul Slawek2 ; Francesca Mosca2
1 Department of Biology, University of Texas Arlington, USA
2 Department of Chemistry and Biochemistry, Florida Atlantic University, USA
Received: Apr 23, 2018
Accepted: Aug 01, 2018
Published Online: Aug 08, 2018
Authors
Ahmed El-Sharkawy1,2; Ahmed Malki3*
1 Human Molecular Genetics Laboratory, Institute of Genetics and Biophysics “A. Buzzati-Traverso” (IGB)-CNR, Naples, Italy
2 Biomolecular Science Programme, Università DegliStudi Della Campania “Luigi Vanvitelli”, Naples, Italy
3 Biomedical science Department, College of Health Sciences, Qatar University, Doha, Qatar
Received: Apr 26, 2018
Accepted: Oct 12, 2018
Published Online: Oct 19, 2018
Authors
Farouq Salih; Francois Calaud; Kakil Rasul*; Mufid Elmistiri; Nabil Elhadi; Hafez Gazouani; Salha Bujassoum
Department of Medical Oncology, Breast Cancer Team, National Center for Cancer Care and Research -HMC - Qatar
Received: Sep 26, 2018
Accepted: Oct 25, 2018
Published Online: Nov 02, 2018
